Clinical trials: Acromegaly
Acromegaly
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
To evaluate the long-term efficacy and safety of repeated injections of lanreotide Autogel given in doses titrated to effect in acromegalic patients previously treated or not with somatostatin analogues.
- Trial name
- NCT00210457
- Testing
- Lanreotide (Autogel formulation)
- Where
- 17 sites in France, Switzerland
- Volunteers
- 63 people
- Sponsor
- Ipsen
Acromegaly
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
The patients received either Pasireotide LAR or Octreotide LAR for one year of treatment. The objective of this study was to compare the proportion of patients with a reduction of mean GH level to <2.5 µg/L and the normalization…
- Trial name
- NCT00600886
- Testing
- Pasireotide, Octreotide
- Where
- 95 sites in United States, Argentina and 25 more
- Volunteers
- 358 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
The morbidity and the mortality in acromegalic patients closely correspond to growth hormone (GH) levels and therefore efficient long-term treatment is important.
- Trial name
- NCT00145405
- Testing
- Lanreotide Autogel and Octreotide LAR
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Odense University Hospital
Acromegaly
Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
The purpose of this study is to assess the safety and efficacy of extended dosing with IONIS GHR-LRx in participants with acromegaly as add-on to somatostatin receptor ligands (SRL) therapy.
- Trial name
- NCT03967249
- Testing
- IONIS GHR-LRx, Somatostatin Receptor Ligand (SRL)
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 39 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Acromegaly
Acromegaly Combination Treatment Study
In this study the investigators will evaluate whether combination low dose somatostatin receptor ligand (SRL) and weekly or daily pegvisomant will attain equivalent control of serum insulin-like growth factor (IGF)-1 levels at a…
- Trial name
- NCT01538966
- Testing
- Pegvisomant, Octreotide LAR, Lanreotide
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Cedars-Sinai Medical Center
Acromegaly
Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients
Currently, the first line treatment for acromegaly is surgery, in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly.
- Trial name
- NCT00128232
- Testing
- Octreotide LAR
- Volunteers
- 100 people
- Sponsor
- Novartis
Acromegaly
A Study to Evaluate MAR002 for Acromegaly
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly
- Trial name
- NCT07641179
- Testing
- MAR002
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Marea Therapeutics
Acromegaly
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
Acromegaly is a rare, serious condition characterized by chronic hypersecretion of growth hormone (GH), generally caused by a GH-secreting pituitary adenoma.
- Trial name
- NCT00171730
- Testing
- Pasireotide
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Study of MAR002 in Healthy Men
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men
- Trial name
- NCT07195175
- Testing
- MAR002
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Marea Therapeutics
Cushing's Disease, Acromegaly
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
The study was designed to investigate the optimal management of hyperglycemia developed during pasireotide treatment in participants with Cushing's disease or Acromegaly, which was not manageable with metformin.
- Trial name
- NCT02060383
- Testing
- Pasireotide s.c., Sitagliptin, Liraglutide
- Where
- 43 sites in United States, Belgium and 10 more
- Volunteers
- 249 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly, Pituitary Neoplasm
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
The purpose of this study is to compare the efficacy of Sandostatin LAR® (Registered Trademark) Depot to transsphenoidal surgery in previously untreated acromegalic patients with macroadenomas.
- Trial name
- NCT00001860
- Testing
- Sandostatin LAR Depot versus transsphenoidal surgery
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acromegaly
Acromegaly & Sleep Apnoea
Estimates of the prevalence of acromegaly, a condition resulting from excess growth hormone secretion, are as high as 1:1000. If detected late acromegaly increases the risk of joint destruction, heart disease, sleep apnoea, high…
- Trial name
- NCT02371057
- Where
- United Kingdom
- Volunteers
- 653 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Quality of Life, Acromegaly
Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
Study Synopsis Study Title: Double blind, single centre, cross-over study on the effects of weekly subcutaneous administration of 40 mg pegvisomant or placebo on quality of life and insulin sensitivity in acromegalic patients…
- Trial name
- mec-2005-290 (NCT00642720)
- Testing
- Pegvisomant
- Volunteers
- 20 people
- Sponsor
- Erasmus Medical Center
Acromegaly
The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research
This study is a prospective, noninteractive, observational, and longitudinal study aimed at assessing the treatment pattern and clinical outcome of acromegaly in China.
- Trial name
- NCT03158090
- Testing
- Transnasal butterfly surgery, sandostatin, radiotherapy
- Where
- China
- Volunteers
- 1,965 people
- Sponsor
- Ginkgo Leaf Center for Rare Disorders
Acromegaly Cardiomyopathy
Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy
Pathophysiology of acromegaly cardiomyopathy is yet unclear and a specific treatment have not been indicated. It was already demonstrated the positive impact of phosphodiesterase type 5A (PDE5A) inhibition in several models of…
- Trial name
- SUM (NCT02611336)
- Testing
- Tadalafil
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Andrea M. Isidori
Pituitary Tumor
Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma
The purpose of the study is to determine genetic links among blood-relatives and between spouses of patients with pituitary tumors.
- Trial name
- NCT00598949
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Cedars-Sinai Medical Center
Acromegaly Due to Pituitary Adenoma, Ketogenic Diet
KETOgenic Diet Therapy in Patients With ACROmegaly
Acromegaly is caused by a tumour located at the base of the brain in the pituitary gland that produces too much growth hormone (GH).
- Conditions
- Acromegaly Due to Pituitary Adenoma, Ketogenic Diet, Mediterranean Diet
- Trial name
- KETOACRO (NCT06949891)
- Testing
- Ketogenic diet, Mediterranean diet
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Erasmus Medical Center
Acromegaly
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical product octreotide used to treat acromegaly.
- Trial name
- NCT01412424
- Testing
- Octreotide capsules
- Where
- 36 sites in United States, Germany and 11 more
- Volunteers
- 155 people
- Sponsor
- Chiasma, Inc.
Acromegaly
Ultrasound Guided Octreotide LAR Injection in Acromegaly
Approximately half of patients with acromegaly do not respond to treatment with somatostatin receptor ligands such as octreotide LAR.
- Trial name
- NCT00552071
- Testing
- Octreotide LAR 30 MG Injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Cedars-Sinai Medical Center
Acromegaly
Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
The purpose of this study is to assess the safety profile of C2L-OCT-01 PR for up to an additional 96-week period in acromegalic patients who completed the C2L-OCT-01 PR-301 study.
- Trial name
- NCT00635765
- Testing
- C2L-OCT-01 PR 30 mg
- Where
- 6 sites in Belarus, Hungary and 4 more
- Volunteers
- 63 people
- Sponsor
- Ambrilia Biopharma, Inc.